s.lin schreef op 6 januari 2021 08:15:
[...]
mooi gevonden
- Did CDZ173 decrease the patients’ main PSS symptoms?
After 12 weeks of treatment, CDZ173 slightly decreased the patients’ main PSS symptoms. But,
this difference was too small for the researchers to know if it was caused by the trial drug.
The researchers wanted to know if CDZ173 decreased the patients’ main PSS symptoms. To find
out, the trial doctors used questions from the EULAR Sjögren’s Syndrome Patient Reported Index,
also called the ESSPRI. The patients filled out the ESSPRI before, during, and after treatment.
The ESSPRI is a questionnaire that measures how severe patients’ main PSS symptoms are. The
patients in this trial scored their tiredness, pain, and dryness symptoms each on a scale from 0 to 10.
Lower scores meant that the symptoms were less severe.
Na 12 weken behandeling verminderde CDZ173 de belangrijkste PSS-symptomen van de patiënten enigszins. Maar,
dit verschil was te klein voor de onderzoekers om te weten of het werd veroorzaakt door het proefmedicijn.
- Adverse events during this trial (Bijwerkingen tijdens deze proef ) pagina 6 en 7
bijwerkingen zijn wel hoog te noemen